AU2002255478A1 - Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof - Google Patents

Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Info

Publication number
AU2002255478A1
AU2002255478A1 AU2002255478A AU2002255478A AU2002255478A1 AU 2002255478 A1 AU2002255478 A1 AU 2002255478A1 AU 2002255478 A AU2002255478 A AU 2002255478A AU 2002255478 A AU2002255478 A AU 2002255478A AU 2002255478 A1 AU2002255478 A1 AU 2002255478A1
Authority
AU
Australia
Prior art keywords
transcripts
kits
majority
nucleic acid
detecting expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002255478A
Inventor
Mark Adams
Peter W. D. Li
Eugene W. Myers
Craig J. Venter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Biosystems Inc
Original Assignee
PE Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PE Corp filed Critical PE Corp
Publication of AU2002255478A1 publication Critical patent/AU2002255478A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002255478A 2001-01-10 2002-01-10 Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof Abandoned AU2002255478A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75669601A 2001-01-10 2001-01-10
US09/756,696 2001-01-10
PCT/US2002/000284 WO2002068579A2 (en) 2001-01-10 2002-01-10 Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Publications (1)

Publication Number Publication Date
AU2002255478A1 true AU2002255478A1 (en) 2002-09-12

Family

ID=25044658

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002255478A Abandoned AU2002255478A1 (en) 2001-01-10 2002-01-10 Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Country Status (2)

Country Link
AU (1) AU2002255478A1 (en)
WO (1) WO2002068579A2 (en)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1472352A4 (en) * 2000-03-06 2005-10-12 Smithkline Beecham Corp Novel compounds
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1666594A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
EP1939293A3 (en) * 2000-06-30 2008-07-09 ZymoGenetics, Inc. Interferon-Like Protein ZCYTO21
US20040254348A1 (en) * 2000-07-12 2004-12-16 Shuji Hinuma Novel polypeptide and dna thereof
AU2001229503A1 (en) * 2000-08-28 2002-03-13 Human Genome Sciences, Inc. 17 human secreted proteins
JP4503801B2 (en) * 2000-09-08 2010-07-14 独立行政法人科学技術振興機構 Novel human cancer / testis antigen and its gene
US20060063152A1 (en) 2000-12-22 2006-03-23 Osamu Ohara Novel gene and protein encoded by the gene
JPWO2002061076A1 (en) * 2001-02-01 2004-06-03 持田製薬株式会社 Adiponectin-related protein
EP1434783A4 (en) * 2001-03-16 2006-06-07 Lilly Co Eli Lp mammalian proteins; related reagents
EP1373306A4 (en) * 2001-03-29 2005-07-20 Incyte Genomics Inc Cytoskeletion-associated proteins
AU2002307250B2 (en) * 2001-04-10 2006-09-14 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer
US7309760B2 (en) 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
AU2002338582A1 (en) * 2001-04-26 2002-11-11 Gong, Fancheng Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
AUPR470101A0 (en) * 2001-05-02 2001-05-24 Murdoch Childrens Research Institute, The A molecular marker
MXPA03010052A (en) * 2001-05-03 2004-04-02 Akzo Nobel Nv Peptidylarginine deiminase 6.
JP2005505258A (en) 2001-06-21 2005-02-24 イシス・イノベイション・リミテッド ANGE gene in atopy
US20030120040A1 (en) 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
EP1523308A4 (en) 2001-07-20 2007-01-10 Us Gov Health & Human Serv Phenylthiocarbamide (ptc) taste receptor
US7833779B2 (en) 2001-07-25 2010-11-16 Jivan Biologies Inc. Methods and systems for polynucleotide detection
US7340349B2 (en) * 2001-07-25 2008-03-04 Jonathan Bingham Method and system for identifying splice variants of a gene
JP2005503150A (en) * 2001-08-17 2005-02-03 インサイト・ゲノミックス・インコーポレイテッド Secreted protein
JP2005504546A (en) * 2001-08-17 2005-02-17 インサイト・ゲノミックス・インコーポレイテッド Intracellular signaling molecules
EP1448600A4 (en) 2001-09-07 2004-12-22 Bristol Myers Squibb Co Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39
EP1428877A4 (en) * 2001-09-17 2004-11-17 Takeda Chemical Industries Ltd Novel protein and dna thereof
JP2005504534A (en) 2001-09-19 2005-02-17 アメリカ合衆国政府 Transductin-1 and transductin-2 and application to hereditary hearing impairment
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US8124052B2 (en) * 2003-02-10 2012-02-28 Georgetown University Method for identifying targeting domains and methods and compositions comprising the same
CA2476518A1 (en) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7642242B2 (en) 2002-03-05 2010-01-05 Genentech, Inc. PRO34128 polypeptides
US7247446B2 (en) 2002-03-05 2007-07-24 Genentech, Inc. PRO34128 nucleic acids
DE10211088A1 (en) 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
EP2258872B1 (en) 2002-03-13 2013-08-14 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US7223580B2 (en) * 2002-03-14 2007-05-29 National Institute Of Advanced Industrial Science And Technology N-acetylglucosamine transferase, nucleic acid encoding the same and use thereof in diagnosing cancer and/or tumor
WO2003091402A2 (en) * 2002-04-23 2003-11-06 University Of Georgia Research Foundation, Inc. N-ACETYLGLUCOSAMINYLTRANSFERASE Vb CODING SEQUENCE, RECOMBINANT CELLS AND METHODS
AU2003269880A1 (en) * 2002-05-21 2003-12-22 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon
WO2003101401A2 (en) 2002-06-03 2003-12-11 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
EP1572960A4 (en) 2002-07-29 2009-03-18 Senomyx Inc Identification of a novel bitter taste receptor, t2r76
WO2004013347A2 (en) * 2002-08-06 2004-02-12 Curagen Corporation Methods of identifying compounds that modulate protein activity
WO2004016790A1 (en) * 2002-08-14 2004-02-26 National Institute Of Advanced Industrial Science And Technology Novel n-acetylgalactosamine transferases and nucleic acids encoding the same
CA2498771A1 (en) * 2002-09-13 2004-03-25 Sankyo Company Limited 2',5'-oligoadenylate phosphodiesterase
EP2444409A2 (en) * 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003275173A1 (en) * 2002-09-25 2004-04-19 Board Of Regents, The University Of Texas System Endogenous granzyme b in human non-hematopoietic cells
US7700108B2 (en) * 2002-09-27 2010-04-20 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen protein and use thereof
JP4679149B2 (en) 2002-09-30 2011-04-27 オンコセラピー・サイエンス株式会社 Genes and polypeptides related to human pancreatic cancer
EP1558737A4 (en) * 2002-10-18 2008-06-11 Lg Life Sciences Ltd Gene families associated with cancers
GB0224436D0 (en) * 2002-10-21 2002-11-27 Univ Cambridge Tech Polypetides methods and means
EP2322202A3 (en) * 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune diseases
US7288642B1 (en) * 2002-11-07 2007-10-30 Mayo Foundation For Medical Education And Research Sulfotransferase 2B1 pharmacogenetics
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
GB0227908D0 (en) * 2002-11-29 2003-01-08 Univ London Cancer related methods and means
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2007231823B2 (en) * 2003-01-24 2011-07-21 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer
EP1590437A4 (en) 2003-01-24 2008-06-18 Agensys Inc Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
WO2004071269A2 (en) * 2003-02-13 2004-08-26 Intellectual Property Consulting Inc. Gene marker and composition for diagnosis and treatment of neurological disorders and diseases and use of the same
PT1597391E (en) 2003-02-20 2008-12-19 Genomic Health Inc Use of intronic rna to measure gene expression
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
WO2004081170A2 (en) * 2003-03-10 2004-09-23 Ares Trading S.A. Progestin receptor-like protein
PT2248899E (en) 2003-03-19 2015-09-23 Biogen Ma Inc Nogo receptor binding protein
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
WO2004087748A1 (en) * 2003-04-04 2004-10-14 Centre National De La Recherche Scientifique Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same
US7306910B2 (en) 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
FR2854640A1 (en) * 2003-05-07 2004-11-12 Galderma Res & Dev Use of polynucleotide probe specific for the PMP 69 gene in diagnosis of psoriasis and to screen for antipsoriatic agents, also therapeutic use by inhibiting PMP 69 expression or activity
WO2004111273A2 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP1644528A2 (en) 2003-06-19 2006-04-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Variants of human taste receptor genes
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
WO2005044977A2 (en) * 2003-06-25 2005-05-19 Diadexus, Inc. Compositions, splice variants and methods relating to lung specific genes and proteins
WO2005001089A1 (en) * 2003-06-27 2005-01-06 Seikagaku Corporation Method of detecting cancer
WO2005008213A2 (en) 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
DE10332854A1 (en) * 2003-07-18 2005-02-17 Universitätsklinikum der Charité der Humboldt-Universität zu Berlin Use of the newly identified human gene 7a5 / prognostin for tumor diagnostics and tumor therapy
US20070037204A1 (en) 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
EP2311468B1 (en) * 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
AU2003275958A1 (en) * 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
DE602004015626D1 (en) * 2003-08-28 2008-09-18 Ipsogen IN BREAST CANCER
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
DE10341812A1 (en) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
DE10345010A1 (en) * 2003-09-22 2005-04-28 Eike Staub Use of the receptor Nifie14, or nucleic acid encoding it, for detecting cancer, or the risk of developing it, also use of Nifie 14 binding agents for diagnosis and treatment of cancer
DE10344799A1 (en) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
GB0322998D0 (en) * 2003-10-01 2003-11-05 Ares Trading Sa Protein
WO2005051994A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Ztnf11, a tumor necrosis factor
CA3050151C (en) * 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
WO2005052154A1 (en) * 2003-11-27 2005-06-09 Takeda Pharmaceutical Company Limited Method of estimating toxicity of drug
AU2004294527A1 (en) * 2003-12-05 2005-06-16 Erasmus Mc Predicting response and outcome of metastatic breast cancer anti-estrogen therapy
KR20070000438A (en) 2003-12-23 2007-01-02 게노믹 헬쓰, 인코포레이티드 Universal amplification of fragmented rna
WO2005066363A2 (en) * 2004-01-09 2005-07-21 Medigen Biotechnology Corporation Cancer specific gene ccndbp1
WO2005076014A1 (en) * 2004-01-28 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 2 (mglur2)
WO2005075674A1 (en) * 2004-02-04 2005-08-18 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of kcne4 gene and protein for alzheimer disease
US8637236B2 (en) 2004-02-17 2014-01-28 The Hospital For Sick Children MECP2E1 gene
WO2005078099A1 (en) * 2004-02-17 2005-08-25 The Hospital For Sick Children Mecp2e1 gene
WO2005078444A1 (en) * 2004-02-18 2005-08-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human melatonin receptor type 1b (mtnr1b)
WO2005083437A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with integrin-linked kinase 2 (ilk2)
US7166433B2 (en) * 2004-03-03 2007-01-23 The United States Of America As Represented By The Department Of Health And Human Services Transductin-1 and transductin-2 and applications to hereditary deafness
WO2005089505A2 (en) 2004-03-19 2005-09-29 Yale University Detection, isolation and uses of renalase (monoamine oxidase c)
WO2005090569A1 (en) * 2004-03-24 2005-09-29 The Council Of The Queensland Institute Of Medical Research Cancer and testis vsm1 and vsm2 nucleic acids, proteins and uses thereof
EP2112222A1 (en) * 2004-03-31 2009-10-28 Daiichi Pharmaceutical Co., Ltd. Gene encoding guanine nucleotide exchange factor and gene product thereof
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
EP2267458A3 (en) 2004-04-20 2011-04-06 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
PL3404102T3 (en) 2004-04-21 2021-12-13 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
EP1745292A2 (en) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
WO2005113786A2 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chymase (cma1)
US20080038255A1 (en) * 2004-06-04 2008-02-14 Aplied Research Systems Ars Holding N.V. Splice Variant of Unc5h2
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
ES2395094T3 (en) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Treatment of conditions that involve demyelination
US8034553B2 (en) 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20060008876A1 (en) 2004-07-07 2006-01-12 Shami A S E ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis
ATE540973T1 (en) * 2004-07-22 2012-01-15 Five Prime Therapeutics Inc COMPOSITIONS AND METHODS FOR USING MGD-CDF FOR DISEASE TREATMENT
WO2006010516A1 (en) * 2004-07-29 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 like protein (metap2-like)
WO2006022689A1 (en) * 2004-08-06 2006-03-02 Applera Corporation Method and compositions for treating diseases targeting cd51
GB0417887D0 (en) 2004-08-11 2004-09-15 Ares Trading Sa Protein
DK1815014T3 (en) 2004-11-05 2012-06-18 Genomic Health Inc Molecular indicators of breast cancer prognosis and prediction of treatment response
JP2008518626A (en) * 2004-11-05 2008-06-05 アメリカ合衆国 Diagnosis and prognosis of infectious disease clinical phenotypes and other physiological conditions using host gene expression biomarkers in blood
JP5020088B2 (en) 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド Predicting response to chemotherapy using gene expression markers
DE602006014659D1 (en) * 2005-02-02 2010-07-15 Eisai R&D Man Co Ltd METHOD FOR IDENTIFYING PURKINJE CELLS USING THE CORL2 GENE AS A TARGET
WO2006090389A2 (en) 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
DE102005013846A1 (en) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
MX2008000253A (en) 2005-07-08 2008-04-02 Biogen Idec Inc Sp35 antibodies and uses thereof.
GB0515180D0 (en) * 2005-07-22 2005-08-31 Ares Trading Sa Protein
MX2008002101A (en) 2005-08-12 2008-04-19 Schering Corp Mcp1 fusions.
US7488582B2 (en) * 2005-11-02 2009-02-10 Stowers Institute For Medical Research Nucleic acids and associated diagnostics
US7858084B2 (en) 2005-11-21 2010-12-28 Yale University Methods of treatment with renalase (monoamine oxidase C)
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
GB0524648D0 (en) * 2005-12-02 2006-01-11 Ares Trading Sa Reeler domain containing protein
GB0524984D0 (en) * 2005-12-07 2006-01-18 Ares Trading Sa Cys-rich, cell surface glycoproteins
GB0525958D0 (en) * 2005-12-20 2006-02-01 Ares Trading Sa Casein-like secreted protein
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Therapeutic uses of inhibitors of rtp801l
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
KR100873382B1 (en) 2006-12-21 2008-12-10 김현기 Human protooncogene, protein encoded by same, expression vector containing same, and cell transformed by said vector
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008106709A1 (en) * 2007-03-07 2008-09-12 The Council Of The Queensland Institute Of Medical Research NOVEL HUMAN ssDNA BINDING PROTEINS AND METHODS OF CANCER DIAGNOSIS
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
US8163709B2 (en) 2008-01-28 2012-04-24 Board Of Regents Of The University Of Texas System TAK1-D mediated induction of cell death in human cancer cells by specific sequence short double-stranded RNAS
US7879553B2 (en) 2008-03-14 2011-02-01 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
US20110294682A1 (en) * 2008-04-28 2011-12-01 The General Hospital Corporation Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risks
EP2133433A1 (en) * 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
KR101517556B1 (en) * 2008-06-25 2015-05-06 재단법인 한국파스퇴르연구소 Genome wide visual identification of human co-factors of HIV-1 infection
DK2982695T3 (en) 2008-07-09 2019-05-13 Biogen Ma Inc COMPOSITIONS CONCERNING ANTIBODIES AGAINST LINGO OR FRAGMENTS THEREOF
WO2010022145A2 (en) * 2008-08-19 2010-02-25 The University Of North Carolina At Chapel Hill Alternatively-spliced isoform of mu-opioid receptor gene with cell excitatory function
KR101061016B1 (en) 2008-09-17 2011-08-31 강원대학교산학협력단 Polypeptides or fusion proteins thereof having an inhibitory activity against growth of cancer cells and preventive or treating activity against inflammatory diseases
KR101062167B1 (en) * 2008-10-23 2011-09-05 사회복지법인 삼성생명공익재단 A composition for treating cancer comprising a Vir 2.2 inhibitor
JPWO2010092974A1 (en) * 2009-02-11 2012-08-16 国立大学法人 東京大学 Brain tumor stem cell differentiation promoter and brain tumor therapeutic agent
CA2755784C (en) 2009-03-16 2020-03-24 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
US20110097329A1 (en) 2009-06-26 2011-04-28 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8435961B2 (en) 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
JP5871798B2 (en) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント How to stimulate liver regeneration
KR20120130748A (en) 2009-11-05 2012-12-03 알렉시온 캠브리지 코포레이션 Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
ES2535951T3 (en) 2009-12-11 2015-05-19 Atyr Pharma, Inc. Histidyl tRNA synthetases to reduce inflammation
PT105029B (en) * 2010-03-29 2012-09-11 Univ Do Minho NUCLEIC PEPTIDE ACID PROBE, CASE AND METHOD FOR DETECTING AND / OR QUANTIFYING SALMONELLA AND THEIR APPLICATIONS
CA2795554C (en) * 2010-04-06 2021-07-13 Massachusetts Institute Of Technology Gene-expression profiling with reduced numbers of transcript measurements
US10619195B2 (en) 2010-04-06 2020-04-14 Massachusetts Institute Of Technology Gene-expression profiling with reduced numbers of transcript measurements
AU2011245005A1 (en) 2010-04-30 2012-11-22 Alexion Pharma Holding Methods, compositions, and kits for the treatment of matrix mineralization disorders
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
MX2012014975A (en) 2010-06-22 2013-03-12 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3.
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
JP2013541938A (en) * 2010-09-02 2013-11-21 プロビオドルグ エージー In vivo screening model for the treatment of isoQC related disorders
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
SG194842A1 (en) 2011-05-16 2013-12-30 Bayer Ip Gmbh Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
WO2013074837A1 (en) * 2011-11-15 2013-05-23 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
RU2659423C2 (en) 2012-02-16 2018-07-02 ЭйТИР ФАРМА, ИНК. Hystidil-trna-synthetase for treatment of autoimmune and inflammatory diseases
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
JO3623B1 (en) 2012-05-18 2020-08-27 Amgen Inc St2 antigen binding proteins
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014018849A1 (en) * 2012-07-26 2014-01-30 International Park Of Creativity Preparation of biological devices and their use thereof for increasing the production of secondary metabolites from plants
US9428759B2 (en) 2012-07-26 2016-08-30 Casa Luker S.A. Methods for increasing the production of phenolic compounds from Theobroma cacao
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
DK3460054T3 (en) 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-synthetase-Fc conjugates
CN104178489B (en) * 2013-05-23 2017-09-19 安徽医科大学第一附属医院 AAGAB gene mutation bodies and its application
US20170130272A1 (en) * 2014-05-21 2017-05-11 Consiglio Nazionale Delle Ricerche A Diagnostic Marker For Paget's Disease
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (en) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Treating convulsions using recombinant alkaline phosphatase
MX2017009038A (en) 2015-01-08 2017-10-25 Biogen Ma Inc Lingo-1 antagonists and uses for treatment of demyelinating disorders.
JP6868561B2 (en) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat subjects with alkaline phosphatase deficiency
CN108350440A (en) 2015-08-17 2018-07-31 阿雷克森制药公司 The manufacture of alkaline phosphate ester
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017087866A1 (en) 2015-11-20 2017-05-26 Grand Valley State University Nato3 mutant polypeptides and uses thereof
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (en) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat bronchomalacia
US11224637B2 (en) 2017-03-31 2022-01-18 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
JP2020517638A (en) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド Compositions and methods for treating lung inflammation
WO2019036484A1 (en) * 2017-08-15 2019-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of argininosuccinic aciduria
CN110172462B (en) * 2017-08-20 2021-11-30 浙江大学 Gene with promotion effect on generation and development of tumor, expression product and application thereof
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401833D0 (en) * 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands

Also Published As

Publication number Publication date
WO2002068579A2 (en) 2002-09-06
WO2002068579A3 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
AU2002255478A1 (en) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2001245945A1 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
AU2002216035A1 (en) Detection of nucleic acid polymorphisms
AU2002353543A1 (en) Biosensor
AU2003247375A1 (en) Nucleic acid sequencing by signal stretching and data integration
AU2003282548A1 (en) Nano-chem-fet based biosensors
AU2003241871A1 (en) Chemical sensor system
EP1344835A3 (en) Real-time nucleic acid detection processes and compositions
AU2002257076A1 (en) Nucleic acid shuffling
AU2003280603A1 (en) Method of amplifying nucleic acid
AU2001274560A1 (en) Substrate activation kit and method of detecting dna or the like by using the same
AU2003304301A1 (en) Chemical sensor system
AUPS076802A0 (en) Selective nucleic acid amplification
AU2003220249A1 (en) Improved nucleic acid amplification
AU2003235894A1 (en) Method of detecting target nucleic acid
AU2003281867A1 (en) Antisense nucleic acids
AU2003284127A1 (en) Nucleic acid supported protein complementation
AU2003205817A1 (en) Methods of nucleic acid amplification
AU2003247592A1 (en) Selective cloning of homoduplex nucleic acids
AU2003250080A1 (en) Oligonucleotides for detecting micro-organisms
AU1070501A (en) Quantitation of rna transcripts using genomic dna as the internal amplification competitor
AU2003281322A1 (en) Improved method of chemical sensing
AU2003234938A1 (en) Method of identifying nucleic acid
AU2003224265A1 (en) Nucleic acid immunization
AUPQ439699A0 (en) Detection of nucleic acid fragments

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase